🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  2. Rilzabrutinib, Composition of placebo is identical to that of IMP except that 400mg active ingredient is replaced with 400mg mannitol.

    Lacuna Pharma Pty Ltd

    Immune Thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  3. Rimonabant

    Sanofi Pasteur

    Obesity

    phase 3 small molecule terminated

    1 trial

  4. Rina-S

    Genmab A/S

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  5. Risankizumab

    AbbVie

    Psoriasis

    phase 3 small molecule active

    1 trial

  6. Risankizumab

    AbbVie

    Palmoplantar Pustulosis (PPP)

    phase 3 small molecule completed

    1 trial

  7. Risankizumab, Placebo for Risankizumab Solution for injection in prefilled syringe, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  8. Risankizumab, Risankizumab placebo solution for infusion, ABBV-066 / Risankizumab, ABBV-066, Risankizumab placebo solution for injection in pre-filled syringe, Risankizumab

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  9. Rituximab

    Lxo Ireland Designated Activity Company

    Lupus Nephritis

    phase 3 mab terminated

    1 trial

  10. Rituximab

    The First People's Hospital of Lianyungang

    Refractory Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  11. Rituximab

    United Therapeutics Europe Ltd

    Kidney Transplant Rejection

    phase 3 small molecule terminated

    1 trial

  12. Rituximab

    United Therapeutics Europe Ltd

    Follicular Lymphoma

    phase 3 small molecule completed

    1 trial

  13. Rituximab

    Janssen Cilag International NV

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    1 trial

  14. Rituximab

    Hospital Authority, Hong Kong

    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    phase 3 mab completed

    1 trial

  15. Rituximab

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    3 trials

  16. Rituximab (RTX)

    Incyte

    Diffuse Large B-cell Lymphoma

    phase 3 small molecule completed

    1 trial

  17. Rituximab 375 mg/m^2

    Takeda

    Mantle Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  18. Rivaroxaban

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  19. Rivaroxaban (Xarelto, BAY59-7939)

    Bayer HealthCare AG

    Venous Thromboembolism

    phase 3 small molecule completed

    2 trials

  20. Rivaroxaban (Xarelto, BAY59-7939)

    Bayer HealthCare AG

    Prevention & Control

    phase 3 small molecule completed

    1 trial

  21. Rivaroxaban (Xarelto, BAY59-7939)

    Bayer HealthCare AG

    Pulmonary Embolism

    phase 3 small molecule completed

    1 trial

  22. Rivaroxaban 2.5 Mg Oral Tablet

    The George Institute

    Chronic Kidney Diseases

    phase 3 small molecule completed

    1 trial

  23. Rivaroxaban 2.5 mg

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Acute Coronary Syndrome

    phase 3 small molecule completed

    1 trial

  24. RoActemra 20 mg/mL concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Neulasta 6 mg solution for injection, AZD0486, RoActemra 20 mg/mL concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Ribodoxo® 2 mg/ml Injektionslösung, Prednison 20 mg GALEN®, AZD0486, Endoxan 500 mg, poeder voor oplossing voor injectie, Ruxience 500 mg concentrate for solution for infusion

    AstraZeneca AB

    Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources